Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors

Catherina X. Pan,Mofei Liu,Charles B. Lau,William C. Lau,Daniel Y. Kim, Shahin A. Saberi, Rachael Rowley, Ruhi Kanwar,Anita Giobbie-Hurder,Nicole R. Leboeuf,Vinod E. Nambudiri

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2024）

Cited 0|Views4

No score

Key words

connective tissue disease,Ehlers-Danlos,None disclosed.,BRAF,histopathology,immune check- point inhibitor,immune-related adverse events,immunotherapy,irAEs,lymphovascular inva- sion,melanoma,mitotic rate,NRAS,regression,toxicity,tumor infiltrating lymphocytes,tumor mutation

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined